Dimitri Lavillette

List of Publications by Year
in descending order

33 papers	2,219 citations	411340 20 h-index	425179 34 g-index
42 all docs	42 docs citations	42 times ranked	3410 citing authors

#	Article	IF	Citations
1	Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein. Emerging Microbes and Infections, 2022, 11, 351-367.	3.0	19
2	SARS-CoV-2 spike engagement of ACE2 primes S2â€² site cleavage and fusion initiation. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	60
3	Isolation, characterization, and structure-based engineering of a neutralizing nanobody against SARS-CoV-2. International Journal of Biological Macromolecules, 2022, 209, 1379-1388.	3.6	3
4	Structural Characterization of a Neutralizing Nanobody With Broad Activity Against SARS-CoV-2 Variants. Frontiers in Microbiology, 2022, 13, .	1.5	5
5	Zika virus pathogenesis and current therapeutic advances. Pathogens and Global Health, 2021, 115, 21-39.	1.0	23
6	The SARS-CoV-2 envelope and membrane proteins modulate maturation and retention of the spike protein, allowing assembly of virus-like particles. Journal of Biological Chemistry, 2021, 296, 100111.	1.6	211
7	Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections. Nature Communications, 2021, 12, 264.	5.8	81
8	A high-affinity RBD-targeting nanobody improves fusion partnerâ€™s potency against SARS-CoV-2. PLoS Pathogens, 2021, 17, e1009328.	2.1	37
9	Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines. Viruses, 2021, 13, 1421.	1.5	6
10	A synthetic nanobody targeting RBD protects hamsters from SARS-CoV-2 infection. Nature Communications, 2021, 12, 4635.	5.8	72
11	Uncovering a conserved vulnerability site in SARSâ€CoVâ€2 by a human antibody. EMBO Molecular Medicine, 2021, 13, e14544.	3.3	17
12	Immunization with the receptor-binding domain of SARS-CoV-2 elicits antibodies cross-neutralizing SARS-CoV-2 and SARS-CoV without antibody-dependent enhancement. Cell Discovery, 2020, 6, 61.	3.1	52
13	A new class of broadly neutralizing antibodies that target the glycan loop of Zika virus envelope protein. Cell Discovery, 2020, 6, 5.	3.1	20
14	Yeast-produced subunit protein vaccine elicits broadly neutralizing antibodies that protect mice against Zika virus lethal infection. Antiviral Research, 2019, 170, 104578.	1.9	15
15	Comparative study of chikungunya Virus-Like Particles and Pseudotyped-Particles used for serological detection of specific immunoglobulin M. Virology, 2019, 529, 195-204.	1.1	10
16	Role of Hepatitis C Virus Envelope Glycoprotein E1 in Virus Entry and Assembly. Frontiers in Immunology, 2018, 9, 1411.	2.2	33
17	Negligible contribution of M2634V substitution to ZIKV pathogenesis in AG6 mice revealed by a bacterial promoter activity reduced infectious clone. Scientific Reports, 2018, 8, 10491.	1.6	24
18	A protein coevolution method uncovers critical features of the Hepatitis C Virus fusion mechanism. PLoS Pathogens, 2018, 14, e1006908.	2.1	20

#	Article	IF	Citations
19	Co-Infection of Mosquitoes with Chikungunya and Dengue Viruses Reveals Modulation of the Replication of Both Viruses in Midguts and Salivary Glands of Aedes aegypti Mosquitoes. International Journal of Molecular Sciences, 2017, 18, 1708.	1.8	48
20	Histone demethylase LSD1 restricts influenza A virus infection by erasing IFITM3-K88 monomethylation. PLoS Pathogens, 2017, 13, e1006773.	2.1	29
21	Specialization of Hepatitis C Virus Envelope Glycoproteins for B Lymphocytes in Chronically Infected Patients. Journal of Virology, 2016, 90, 992-1008.	1.5	9
22	The Sheep Tetherin Paralog oBST2B Blocks Envelope Glycoprotein Incorporation into Nascent Retroviral Virions. Journal of Virology, 2015, 89, 535-544.	1.5	9
23	The Mechanism of HCV Entry into Host Cells. Progress in Molecular Biology and Translational Science, 2015, 129, 63-107.	0.9	89
24	New Insights into the Understanding of Hepatitis C Virus Entry and Cell-to-Cell Transmission by Using the Ionophore Monensin A. Journal of Virology, 2015, 89, 8346-8364.	1.5	18
25	Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs. Blood, 2014, 124, 1221-1231.	0.6	109
26	Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry. Hepatology, 2014, 59, 776-788.	3.6	83
27	Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2. Biochemical Journal, 2012, 443, 85-94.	1.7	42
28	Identification of Interactions in the E1E2 Heterodimer of Hepatitis C Virus Important for Cell Entry. Journal of Biological Chemistry, 2011, 286, 23865-23876.	1.6	25
29	Receptor Complementation and Mutagenesis Reveal SR-BI as an Essential HCV Entry Factor and Functionally Imply Its Intra- and Extra-Cellular Domains. PLoS Pathogens, 2009, 5, e1000310.	2.1	107
30	Characterization of Fusion Determinants Points to the Involvement of Three Discrete Regions of Both E1 and E2 Glycoproteins in the Membrane Fusion Process of Hepatitis C Virus. Journal of Virology, 2007, 81, 8752-8765.	1.5	157
31	Hepatitis C Virus Glycoproteins Mediate Low pH-dependent Membrane Fusion with Liposomes. Journal of Biological Chemistry, 2006, 281, 3909-3917.	1.6	119
32	An Envelope Glycoprotein of the Human Endogenous Retrovirus HERV-W Is Expressed in the Human Placenta and Fuses Cells Expressing the Type D Mammalian Retrovirus Receptor. Journal of Virology, 2000, 74, 3321-3329.	1.5	611
33	Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant. Frontiers in Immunology, 0, 13, .	2.2	6